This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Millions of Americans are born predisposed to high levels of a cholesterol called lipoprotein(a). Doctors are finally figuring out how to treat it.

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...